The International Generic and Biosimilar Medicines Association (IGBA) in line with its goals of promoting the widest possible access to safe, effective, and quality-assured medicines; and of promoting intellectual property regimes which foster innovation and allow the timely entry of generic and biosimilar medicines, has released its report called “GAMING THE SYSTEM- An overview of originator companies’ evergreening strategies used to hinder access to generic and biosimilar products”.

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), International Pharmaceutical Federation (FIP), International Alliance of Patients’ Organizations (IAPO), and International Generic and Biosimilar Medicines Association (IGBA) delivered a statement on Agenda Item 15: WHO’s work in health emergencies.

IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Shinichiro Hirose, Director of International Affairs at the Japanese Generic Medicines Association (JGA) is taking over the position of IGBA Chair for 2025 from Adrian van den Hoven, Director of Medicines for Europe. Jim Keon, President of the Canadian Generic Pharmaceutical Association, will take over the position of IGBA Vice-Chair for 2025.